Optimizing the properties of molecules (materials or drugs) for stronger toughness, lower toxicity, or better bioavailability has been a long-standing challenge. In this context, we propose a molecular optimization framework called Q-Drug (Quantum-inspired optimization algorithm for Drugs) that leverages quantum-inspired algorithms to optimize molecules on discrete binary domain variables. The framework begins by encoding the molecules into binary embeddings using a discrete VAE. The binary embeddings are then used to construct an Ising energy-like objective function, over which the state-of-the-art quantum-inspired optimization algorithm is adopted to find the optima. The binary embeddings corresponding to the optima are decoded to obtain the optimized molecules. We have tested the framework for optimizing drug molecule properties and have found that it outperforms other molecular optimization methods, finding molecules with better properties in 1/20th to 1/10th of the time previously required. The framework can also be deployed directly on various quantum computing equipment, such as laser pulses CIMs, FPGA Ising Machines, and quantum computers based on quantum annealing, among others. Our work demonstrates a new paradigm that leverages the advantages of quantum computing and AI to solve practically useful problems.
Optimizing the properties of molecules (materials or drugs) for stronger toughness, lower toxicity, or better bioavailability has been a long-standing challenge. In this context, we propose a molecular optimization framework called Q-Drug (Quantum-inspired optimization algorithm for Drugs) that leverages quantum-inspired algorithms to optimize molecules on discrete binary domain variables. The framework begins by encoding the molecules into binary embeddings using a discrete VAE. The binary embeddings are then used to construct an Ising energy-like objective function, over which the state-of-the-art quantum-inspired optimization algorithm is adopted to find the optima. The binary embeddings corresponding to the optima are decoded to obtain the optimized molecules. We have tested the framework for optimizing drug molecule properties and have found that it outperforms other molecular optimization methods, finding molecules with better properties in 1/20th to 1/10th of the time previously required. The framework can also be deployed directly on various quantum computing equipment, such as laser pulses CIMs, FPGA Ising Machines, and quantum computers based on quantum annealing, among others. Our work demonstrates a new paradigm that leverages the advantages of quantum computing and AI to solve practically useful problems.
Abstract : We propose a hybrid quantum–classical framework that integrates variational quantum machine learning (QML) for molecular binding affinity prediction with quantum annealing for Pareto-optimal drug formulation design. Leveraging a four-qubit variational circuit, our QML model achieves superior predictive performance compared to state-of-the-art classical baselines, effectively capturing complex molecular interactions. In parallel, we formulate drug formulation optimization as a Quadratic Unconstrained Binary Optimization (QUBO) problem and solve it using D-Wave’s quantum annealer, enabling efficient identification of Pareto-optimal solutions that balance bioavailability, toxicity, and stability. By unifying predictive modeling and combinatorial optimization within a single pipeline, our framework demonstrates the potential of near-term quantum devices to accelerate and enhance critical stages of drug discovery. These findings underscore the transformative role of NISQ-era algorithms in bridging molecular informatics and formulation design, paving the way for scalable, data-driven pharmaceutical innovation.
Quantum computing promises to be a game changer for drug discovery and battery development as it will enable simulations of complex molecular and material systems not possible in classical regimes. Here, we introduce a hardware-aware, hybrid quantum-classical framework designed for practical pharmaceutical and energy problems. Extending state-of-the-art results from quantum machine learning, quantum-inspired optimization, and domain-specific datasets, the model improves both scalability and accuracy as well as interpretability. The proposed method is validated from real-drug and battery chemistry with advantages over the traditional method. This interdisciplinary breakthrough tackles major drawbacks of current quantum approaches and provides a realistic pathway towards industrial implementation in chemistry-led innovation.
Deep generative modeling to stochastically design small molecules is an emerging technology for accelerating drug discovery and development. However, one major issue in molecular generative models is their lower frequency of drug-like compounds. To resolve this problem, we developed a novel framework for optimization of deep generative models integrated with a D-Wave quantum annealing computer, where our Neural Hash Function (NHF) presented herein is used both as the regularization and binarization schemes simultaneously, of which the latter is for transformation between continuous and discrete signals of the classical and quantum neural networks, respectively, in the error evaluation (i.e., objective) function. The compounds generated via the quantum-annealing generative models exhibited higher quality in both validity and drug-likeness than those generated via the fully-classical models, and was further indicated to exceed even the training data in terms of drug-likeness features, without any restraints and conditions to deliberately induce such an optimization. These results indicated an advantage of quantum annealing to aim at a stochastic generator integrated with our novel neural network architectures, for the extended performance of feature space sampling and extraction of characteristic features in drug design.
This paper explores the potential of quantum machine learning (QML) in revolutionizing drug molecule design. Traditional drug discovery is a time-consuming and expensive process, often hampered by the limitations of classical computational methods in accurately simulating molecular interactions. Quantum computing, with its inherent ability to model quantum phenomena, offers a promising avenue for overcoming these challenges. This work investigates the application of QML algorithms to predict molecular properties, simulate drug-target interactions, and ultimately guide the design of novel drug molecules. Specifically, we outline a framework leveraging quantum algorithms for variational quantum eigensolver (VQE) and quantum approximate optimization algorithm (QAOA) to tackle the complexities of molecular simulations. The core claim is that QML can accelerate the drug development pipeline by providing more accurate and efficient predictions. The mechanism relies on the ability of QML models to capture the subtle quantum effects governing molecular interactions, leading to improved predictions of binding affinities, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties, and overall drug efficacy. This paper lays the groundwork for future research in this emerging field, highlighting the potential for QML to significantly reshape the landscape of pharmaceutical research and development.
Molecular docking (MD) is a crucial task in drug design, which predicts the position, orientation, and conformation of the ligand when bound to a target protein. It can be interpreted as a combinatorial optimization problem, where quantum annealing (QA) has shown promising advantage for solving combinatorial optimization. In this work, we propose a novel quantum molecular docking (QMD) approach based on QA-inspired algorithm. We construct two binary encoding methods to efficiently discretize the degrees of freedom with exponentially reduced number of bits and propose a smoothing filter to rescale the rugged objective function. We propose a new quantum-inspired algorithm, hopscotch simulated bifurcation (hSB), showing great advantage in optimizing over extremely rugged energy landscapes. This hSB can be applied to any formulation of objective function under binary variables. An adaptive local continuous search is also introduced for further optimization of the discretized solution from hSB. Concerning the stability of docking, we propose a perturbation detection method to help ranking the candidate poses. We demonstrate our approach on a typical dataset. QMD has shown advantages over the search-based Autodock Vina and the deep-learning DIFFDOCK in both re-docking and self-docking scenarios. These results indicate that quantum-inspired algorithms can be applied to solve practical problems in the drug discovery even before quantum hardware become mature.
Quantum Machine Learning (QML) offers a transformative approach to drug design and optimization, addressing longstanding challenges in identifying novel drug candidates and refining existing ones. This paper explores the potential of QML to accelerate the drug discovery process by leveraging quantum algorithms for molecular structure exploration and optimization. We present a novel framework incorporating quantum simulation and machine learning, demonstrating its efficacy in predicting drug-target interactions and optimizing molecular properties. The core mechanism centers around accelerating the identification of promising compounds through enhanced molecular search and optimization, while quantum computational modeling provides unprecedented precision. The integration of quantum machine learning with traditional drug design methods promises to significantly reduce development time and costs, ultimately impacting the pharmaceutical industry.